

FORM TITLE: After-Treatment Follow Up

Relevant SOP: Treatment Assessment and Data Monitoring (SOP TA)

Instructions: Complete this form for the time points indicated below and attach copies of all relevant documentation. Submit completed form and attachments to Sponsor.

Protocol Case #: _____ **Date of Visit:** ____MM/____DD/____YY
Patient Name: _____ **or Initials and DOB:** ____MM/____DD/____YY

A. Time Points calculated from the completion of radiation

- 3 months*+
- 6 months
- 12 months+
- 18 months
- 24 months

Schedule prostate biopsy (22-26 months after radiation completion)
Date planned: _____ or
Date completed: _____
Send biopsy slides with PT form

After 24 months visit (every 6 months)

After 5 years, use Long Term Follow Up form (form LT)

(If visit occurs before 3 months as standard of care, please provide a one-time Variance form for your institution)
(+AT 3 and 12 months, also send BS form if participating in optional blood collection for immune studies)*

(Follow-up for patients with treatment failure or discontinuation please indicate the closest time point above and provide prostate cancer general health status data from SOC visits).

B. Evaluations:

History and physical/clinical note attached: Yes No

Are there GI or urinary symptoms? Yes No If yes, complete page 3.

Are there *new* medical problems? Yes No If yes, complete page 2 or attach institutional form.

DRE performed (if standard of care)? Yes No

DRE result: normal or abnormal. If known, estimated dimensions (cm): ____x____ or volume ____

Other details (if not in the clinical note): _____

PSA* (as per standard of care) result attached? Yes, If No, explain: _____

**If progression/recurrence suspected, required studies prior to declaring failure are listed on Form TF.*

Other if clinically indicated (e.g., imaging): Yes No If yes, specify: _____

QOL attached (required until the 24-month visit)? Yes No If no, explain: _____

C. Additional Treatment for Prostate Cancer

If the patient is thought to have developed recurrence since last visit, contact Sponsor prior to patient receiving additional therapy to discuss plan and decide whether a Treatment Failure form (TF) is needed.

Has patient developed recurrence/progression? Yes No

Has patient received additional treatment for prostate cancer since the last visit? Yes No

If yes, please indicate treatment received:

D. New Medical Problems

If patient has been diagnosed with any new medical problems, please describe below:

Diagnosis

Autoimmune/Rheumatological _____

Comments: _____

Cardiovascular _____

Comments: _____

Dermatologic _____

Comments: _____

Endocrine _____

Comments: _____

Gastrointestinal _____

Comments: _____

Hematologic/Oncologic _____

Comments: _____

Infection (chronic) _____

Comments: _____

Neurological _____

Comments: _____

Orthopedic/Musculoskeletal _____

Comments: _____

Pulmonary/Upper Respiratory _____

Comments: _____

Psychiatric _____

Comments: _____

Renal/Genitourinary _____

Comments: _____

Sexual/Reproductive _____

Comments: _____

Surgical _____

Comments: _____

Other: _____

General Comments:

E. Gastrointestinal & Urinary Symptom Grading: If present, check the grade.

ADL= Activities of daily living

	Symptom	CTC Grade 1	CTC Grade 2	CTC Grade 3	CTC Grade 4
Gastrointestinal	Constipation	<input type="checkbox"/> Occasional/intermittent symptoms; occasional use of stool softeners, laxatives, dietary modification, or enema	<input type="checkbox"/> Persistent symptoms with regular use of laxatives or enemas; limiting instrumental ADL	<input type="checkbox"/> Obstipation with manual evacuation indicated; limiting self-care ADL	<input type="checkbox"/> Life-threatening consequences; urgent intervention indicated
	Diarrhea	<input type="checkbox"/> Increase of <4 stools per day over baseline	<input type="checkbox"/> Increase of 4 – 6 stools per day over baseline	<input type="checkbox"/> ≥7 stools per day over baseline; incontinence; hospitalization indicated	<input type="checkbox"/> Life-threatening consequences; urgent intervention indicated
	Fecal incontinence	<input type="checkbox"/> Occasional use of pads required	<input type="checkbox"/> Daily use of pads required	<input type="checkbox"/> Severe symptoms; elective operative intervention indicated	-
	Hemorrhoids	<input type="checkbox"/> Asymptomatic; clinical or diagnostic observations only; intervention not indicated	<input type="checkbox"/> Symptomatic; banding or medical intervention indicated	<input type="checkbox"/> Severe symptoms; radiologic, endoscopic or elective operative intervention indicated	-
	Proctitis	<input type="checkbox"/> Rectal discomfort, intervention not indicated	<input type="checkbox"/> Symptoms (e.g., rectal discomfort, passing blood or mucus); medical intervention; limiting instrumental ADL	<input type="checkbox"/> Severe symptoms; fecal urgency or stool incontinence; limiting self-care ADL	<input type="checkbox"/> Life-threatening consequences; urgent intervention indicated
	Rectal hemorrhage	<input type="checkbox"/> Mild; intervention not indicated	<input type="checkbox"/> Moderate symptoms; medical intervention or minor cauterization indicated	<input type="checkbox"/> Transfusion, radiologic, endoscopic, or elective operative intervention indicated	<input type="checkbox"/> Life-threatening consequences; urgent intervention indicated
	Other, specify:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Renal/Urinary	Hematuria	<input type="checkbox"/> Asymptomatic; clinical or diagnostic observations only; intervention not indicated	<input type="checkbox"/> Symptomatic; urinary catheter or bladder irrigation indicated; limiting instrumental ADL	<input type="checkbox"/> Gross hematuria, transfusion, IV medication or hospitalization; elective endoscopic, radiologic or operative intervention; limiting self-care ADL	<input type="checkbox"/> Life-threatening consequences; urgent radiologic or operative intervention indicated
	Urinary frequency	<input type="checkbox"/> Present	<input type="checkbox"/> Limiting instrumental ADL; medical management indicated	-	-
	Urinary incontinence	<input type="checkbox"/> Occasional (e.g., with coughing, sneezing, etc.), pads not indicated	<input type="checkbox"/> Spontaneous; pads indicated; limiting instrumental ADL	<input type="checkbox"/> Intervention indicated (e.g. clamp, collagen injections, operation); limiting self-care ADL	-
	Urinary retention	<input type="checkbox"/> Catheter placement not indicated; able to void with some residual	<input type="checkbox"/> Placement of urinary, suprapubic or intermittent catheter or medication indicated	<input type="checkbox"/> Elective operative or radiologic intervention; substantial loss of affected kidney function or mass	<input type="checkbox"/> Life-threatening consequences; organ failure; urgent operative intervention indicated
	Urinary tract pain	<input type="checkbox"/> Mild pain	<input type="checkbox"/> Moderate pain; limiting instrumental ADL	<input type="checkbox"/> Severe pain; limiting self-care ADL	-
	Urinary urgency	<input type="checkbox"/> Present	<input type="checkbox"/> Limiting instrumental ADL; medical management indicated	-	-
	Other, specify:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Name and Signature of the person who completed this form _____

Fax (617-916-5444) or email (crf@candeltx.com) to Candel Therapeutics.